PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?
touchCONGRESS for touchONCOLOGY
Listen to three experts explore the latest data from the ESGO European Congress on Gynaecological Oncology 2022 on the use of PARP inhibitors in first-line maintenance therapy for advanced ovarian cancer.
The experts
Prof. Jonathan Ledermann, UCL Cancer Institute, London, UK
Dr David Tan, National University Cancer Institute, Singapore
Dr Anna Tinker, BC Cancer, Vancouver, Canada
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from GlaxoSmithKline. This medical education is provided by touchIME.
For further…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.